Women who receive in vitro fertilisation treatment do not have a higher risk of developing breast cancer in the long term versus those who receive non-IVF therapy and the general population, say Dutch researchers.
Two studies have independently identified quantitative hepatitis B surface antigen as a marker to identify pregnant women with chronic hepatitis B virus infection whose infants are at high-risk of infection despite immunoprophylaxis.
Treatment with the antiangiogenesis inhibitor trebananib does not adversely affect health-related quality of life in patients with recurrent ovarian cancer, suggests the placebo-controlled TRINOVA-1 trial.
Both female and male chemotherapy-treated survivors of childhood cancer have an increased risk of impaired fertility, but results suggest that the risk in women is limited to those given specific chemotherapy drugs.
Oral contraceptive use protects against endometrial cancer, with effects persisting for decades after cessation of use, shows a meta-analysis of individual patient data published in The Lancet Oncology.
Fewer than three doses of the bivalent human papillomavirus vaccine may be sufficient to offer adequate protection against cervical HPV-16 and -18 infection, research published in The Lancet Oncology indicates.
Research shows that the use of α1-blockers in combination with uroflowmetry biofeedback is more effective than either treatment alone for improving urinary symptoms and quality of life in women with dysfunctional voiding and recurrent urinary tract infection.